Barclays PLC Inhibrx, Inc. Transaction History
Barclays PLC
- $288 Billion
- Q1 2024
A detailed history of Barclays PLC transactions in Inhibrx, Inc. stock. As of the latest transaction made, Barclays PLC holds 282,303 shares of INBX stock, worth $4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
282,303
Previous 88,865
217.68%
Holding current value
$4 Million
Previous $3.11 Million
217.81%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding INBX
# of Institutions
132Shares Held
35.5MCall Options Held
64.8KPut Options Held
91.3K-
Viking Global Investors LP7.15MShares$101 Million0.95% of portfolio
-
Perceptive Advisors LLC New York, NY4.26MShares$60.3 Million3.12% of portfolio
-
Black Rock Inc. New York, NY2.75MShares$39 Million0.0% of portfolio
-
State Street Corp Boston, MA2.42MShares$34.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.86MShares$26.4 Million0.0% of portfolio
About Inhibrx, Inc.
- Ticker INBX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,057,700
- Market Cap $553M
- Description
- Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...